Supplementary Table 1. List of adverse events of special interest

Respiratory adverse events including cough and paradoxical bronchospasm	Skin atrophy
Asthma worsening/asthma exacerbation	Skin contusion
Serious asthma-related events (asthma hospitalisations, intubations, deaths)	Psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression
Local oral adverse events	Glaucoma
Local immunosuppressive effects, infections	Hypokalaemia
Anaphylactic reactions	Hyperglycaemia / increased blood glucose
Adrenal suppression/adrenal failure	Cardiac arrhythmias and QTc prolongation
Growth retardation	Cardiac ischaemia
Decrease in bone mineral density	Cataract

Supplementary Table 2. Lung function parameters

Parameter	**Baseline (n=2178–2284)**	**Month 12 (n=1651–1695)**	**End of study (LOCF) (n=2051–2125)**	**Change from baseline to end of study (LOCF) (n=1966–2043)**	
	Mean (SD)	**Mean (SD)**	**Mean (SD)**	**Mean (SD)**	**95% CI**
FEV_1 (L)	2.58 (0.86)	2.71 (0.93)	2.72 (0.93)	0.13 (0.49)*	0.110, 0.154
FEV_1 predicted (%)	84.9 (18.5)	89.0 (19.7)	88.8 (19.8)	4.1 (16.2)*	3.39, 4.81
FVC (L)	3.32 (1.09)	3.41 (1.12)	3.43 (1.12)	0.10 (0.57)*	0.076, 0.127
FVC predicted (%)	91.7 (21.4)	93.7 (18.8)	93.9 (19.1)	2.7 (16.1)*	1.99, 3.40
FEV_1/FVC	0.78 (0.12)	0.80 (0.10)	0.80 (0.12)	0.01 (0.09)*	0.009, 0.016
FEV_1/FVC predicted (%)	98.2 (14.9)	100.1 (12.0)	99.8 (15.3)	1.7 (14.1)*	1.03, 2.27
PEF (L/min)	356.1 (124.7)	373.5 (128.0)	377.0 (127.9)	20.9 (77.4)*	17.49, 24.25
PEF predicted (%)	82.9 (32.2)	88.2 (38.6)	88.2 (35.8)	4.8 (35.7)*	3.24, 6.33

CI, confidence interval; LOCF, last observation carried forward, up to 12 months

* $p < 0.001$ (paired t-test)